Regulatory And Commercial Should Be 'Hand In Hand' For Dx Success, Expert Says
Considering where and how a test will be used, and what kind of evidence regulators will want before clearing it, is key for developers of at home and point-of-care diagnostics.
You may also be interested in...
A report from the Health-ISAC, Finite State and Securin found a large increase in vulnerabilities in healthcare devices since 2022.
Former deputy privacy director of HHS Deven McGraw spoke to Medtech Insight about the shortfalls of the FTC’s proposed health breach notification amendments.
The documents describe the US agency’s preferred approach toward products cleared under EUAs or other alternate approaches during the COVID-19 public health emergency.